The current clinical approach to difficult-to-treat basal cell carcinomas

References

• Asgari MM, Moffet HH, Ray GT, et al. Trends in basal cell carcinoma incidence and identification of high-risk Subgroups, 1998–2012. JAMA Dermatol. 2015;151(9):976–981.
   PubMed Web of Science ®Google Scholar
• Xiang F, Lucas R, Hales S, et al. Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978–2012: empirical relationships. JAMA Dermatol. 2014;150(10):1063–1071.
   PubMed Web of Science ®Google Scholar
• Kim DP, Kus KJB, Ruiz E. Basal Cell Carcinoma Review. Hematol Oncol Clin North Am. 2019;33(1):13–24.
   PubMed Web of Science ®Google Scholar
• Cives M, Mannavola F, Lospalluti L, et al. Non-melanoma skin cancers: biological and clinical features. Int J Mol Sci. 2020;21(15):5394.
   PubMed Web of Science ®Google Scholar
• Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111(8):1476–1481.
   PubMed Web of Science ®Google Scholar
• Peris K, Fargnoli MC, Garbe C, et al. European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10–34.
   PubMed Web of Science ®Google Scholar
• van Dam RM, Huang Z, Rimm EB, et al. Risk factors for basal cell carcinoma of the skin in men: results from the health professionals follow-up study. Am J Epidemiol. 1999;150(5):459–468.
   PubMed Web of Science ®Google Scholar
• Zanetti R, Rosso S, Martinez C, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer. 2006;94(5):743–751.
   PubMed Web of Science ®Google Scholar
• Lichter MD, Karagas MR, Mott LA, et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol. 2000;136(8):1007–1011.
   PubMedGoogle Scholar
• Watt TC, Inskip PD, Stratton K, et al. Radiation-related risk of basal cell carcinoma: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2012;104(16):1240–1250.
   PubMedGoogle Scholar
• Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–1691.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105(5):350–360.
   PubMedGoogle Scholar
• Cassano N, Di Stefani A, Vena GA, et al. Antihypertensive drugs and risk of skin cancer. G Ital Dermatol Venereol. 2018;153(5):672–684.
   PubMed Web of Science ®Google Scholar
• Ruiter R, Visser LE, Eijgelsheim M, et al. High-ceiling diuretics are associated with an increased risk of basal cell carcinoma in a population-based follow-up study. Eur J Cancer. 2010;46(13):2467–2472.
   PubMed Web of Science ®Google Scholar
• Karagas MR, Tosteson TD, Blum J, et al. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect. 1998;106(Suppl 4):1047–1050.
   PubMedGoogle Scholar
• Tao SS, Bolger PM. Dietary arsenic intakes in the United States: FDA total diet study, September 1991-December 1996. Food Addit Contam. 1999;16(11):465–472.
   PubMed Web of Science ®Google Scholar
• Boonchai W, Green A, Ng J, et al. Basal cell carcinoma in chronic arsenicism occurring in Queensland, Australia, after ingestion of an asthma medication. J Am Acad Dermatol. 2000;43(4):664–669.
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Maturo MG, Di Nardo L, et al. Understanding the molecular genetics of basal cell carcinoma. Int J Mol Sci. 2017;18(11):2485.
   PubMed Web of Science ®Google Scholar
• Schierbeck J, Vestergaard T, Bygum A. Skin cancer associated genodermatoses: a literature review. Acta Derm Venereol. 2019;99(4):360–369.
   PubMed Web of Science ®Google Scholar
• Jaju PD, Ransohoff KJ, Tang JY, et al. Familial skin cancer syndromes: increased risk of nonmelanotic skin cancers and extracutaneous tumors. J Am Acad Dermatol. 2016;74(3):437–51; quiz 452–4.
   Web of Science ®Google Scholar
• Reiter O, Mimouni I, Gdalevich M, et al. The diagnostic accuracy of dermoscopy for basal cell carcinoma: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1380–1388.
   PubMed Web of Science ®Google Scholar
• Lallas A, Tzellos T, Kyrgidis A, et al. Accuracy of dermoscopic criteria for discriminating superficial from other subtypes of basal cell carcinoma. J Am Acad Dermatol. 2014;70(2):303–311.
   PubMed Web of Science ®Google Scholar
• Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–179.
   PubMedGoogle Scholar
• Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147(1):41–47.
   PubMed Web of Science ®Google Scholar
• Dourmishev LA, Rusinova D, Botev I. Clinical variants, stages, and management of basal cell carcinoma. Indian Dermatol Online J. 2013;4(1):12–17.
   PubMedGoogle Scholar
• Suppa M, Micantonio T, Di Stefani A, et al. Dermoscopic variability of basal cell carcinoma according to clinical type and anatomic location. J Eur Acad Dermatol Venereol. 2015;29(9):1732–1741.
   PubMed Web of Science ®Google Scholar
• Patterson JW. Weedon’s skin pathology. 4th ed. Lon- 44. don: Churchill-Livingstone; 2016.
   Google Scholar
• Reiter O, Mimouni I, Dusza S, et al. Dermoscopic features of basal cell carcinoma and its subtypes: a systematic review. J Am Acad Dermatol. 2021;85(3):653–664.
   PubMed Web of Science ®Google Scholar
• Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303–317.
   PubMed Web of Science ®Google Scholar
• Pampena R, Parisi G, Benati M, et al. Clinical and dermoscopic factors for the identification of aggressive histologic subtypes of basal cell carcinoma. Front Oncol. 2021;10:630458.
   PubMed Web of Science ®Google Scholar
• Paolino G, Donati M, Didona D, et al. Histology of non-melanoma skin cancers: an update. Biomedicines. 2017;5(4):71.
   PubMed Web of Science ®Google Scholar
• Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol. 1990;23(6 Pt 1):1118–1126.
   PubMed Web of Science ®Google Scholar
• Zalaudek I, Ferrara G, Broganelli P, et al. Dermoscopy patterns of fibroepithelioma of pinkus. Arch Dermatol. 2006;142(10):1318–1322.
   PubMedGoogle Scholar
• Ciążyńska M, Sławińska M, Kamińska-Winciorek G, et al. Clinical and epidemiological analysis of basosquamous carcinoma: results of the multicenter study. Sci Rep. 2020;10(1):18475.
   PubMed Web of Science ®Google Scholar
• Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540–559.
   PubMed Web of Science ®Google Scholar
• Elder DJ, Massi S, Scolyer RA, et al., editors. WHO classification of skin tumors. Lyon: IARC; 2018.
   Google Scholar
• Grob JJ, Guminski A, Malvehy J, et al. Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. J Eur Acad Dermatol Venereol. 2021;35(10):1949–1956.
   PubMed Web of Science ®Google Scholar
• Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev. 2016;42:56–72.
   PubMed Web of Science ®Google Scholar
• Selby P, Popescu R, Lawler M, et al. The value and future developments of multidisciplinary team cancer care. Am Soc Clin Oncol Educ Book. 2019;39:332–340.
   PubMedGoogle Scholar
• Berrocal A, Espinosa E, Marín S, et al. Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma. Eur J Dermatol. 2015;25(5):392–403.
   PubMed Web of Science ®Google Scholar
• Claveau J, Archambault J, Ernst DS, et al. Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma. Curr Oncol. 2020;27(4):e399–e407.
   PubMed Web of Science ®Google Scholar
• Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014;24(3):312–329.
   PubMed Web of Science ®Google Scholar
• Basset-Seguin N, Herms F. Update in the management of basal cell carcinoma. Acta Derm Venereol. 2020;100(11):adv00140.
   PubMedGoogle Scholar
• Newlands C, Currie R, Memon A, et al. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S125–S132.
   PubMedGoogle Scholar
• Nahhas AF, Scarbrough CA, Trotter S. A review of the global guidelines on surgical margins for nonmelanoma skin cancers. J Clin Aesthet Dermatol. 2017;10(4):37–46.
   PubMedGoogle Scholar
• Löser CR, Rompel R, Möhrle M, et al. S1 guideline: microscopically controlled surgery (MCS). J Dtsch Dermatol Ges. 2015;13(9):942–951.
   PubMed Web of Science ®Google Scholar
• Kauvar AN, Cronin T Jr, Roenigk R, et al. Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41(5):550–571.
   PubMed Web of Science ®Google Scholar
• van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50(17):3011–3020.
   PubMed Web of Science ®Google Scholar
• Wain RA, Tehrani H. Reconstructive outcomes of Mohs surgery compared with conventional excision: a 13-month prospective study. J Plast Reconstr Aesthet Surg. 2015;68(7):946–952.
   PubMed Web of Science ®Google Scholar
• McPartlin AJ, Slevin NJ, Sykes AJ, et al. Radiotherapy treatment of non-melanoma skin cancer: a survey of current UK practice and commentary. Br J Radiol. 2014;87(1043):20140501.
   PubMed Web of Science ®Google Scholar
• Halpern JN. Radiation therapy in skin cancer. A historical perspective and current applications. Dermatol Surg. 1997;23(11):1089–1093.
   PubMed Web of Science ®Google Scholar
• Guinot JL, Rembielak A, Perez-Calatayud J, et al. GEC-ESTRO ACROP recommendations in skin brachytherapy. Radiother Oncol. 2018;126(3):377–385.
   PubMed Web of Science ®Google Scholar
• Frakulli R, Galuppi A, Cammelli S, et al. Brachytherapy in non melanoma skin cancer of eyelid: a systematic review. J Contemp Brachytherapy. 2015;7(6):497–502.
   PubMed Web of Science ®Google Scholar
• Porceddu SV. Prognostic factors and the role of adjuvant radiation therapy in non-melanoma skin cancer of the head and neck. Am Soc Clin Oncol Educ Book. 2015;35:e513–8.
   Google Scholar
• Villani A, Cinelli E, Fabbrocini G, et al. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opin Drug Saf. 2020;19(12):1585–1594.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020;34(9):1944–1956.
   PubMed Web of Science ®Google Scholar
• Keating GM. Vismodegib: in locally advanced or metastatic basal cell carcinoma. Drugs. 2012;72(11):1535–1541.
   PubMed Web of Science ®Google Scholar
• Roche Registration Ltd. Erivedge 150 mg hard capsules: EU summary of product characteristics. 2016. http://www.ema.europa.eu. Cited 2018 Jul 6.
   Google Scholar
• Graham RA, Hop CE, Borin MT, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol. 2012;74(5):788–796.
   PubMed Web of Science ®Google Scholar
• Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res. 2011;17(8):2512–2520.
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(17):5774–5782.
   PubMed Web of Science ®Google Scholar
• Lu T, Wang B, Gao Y, et al. Semi-mechanism-based population pharmacokinetic modeling of the hedgehog pathway inhibitor vismodegib. CPT Pharmacometrics Syst Pharmacol. 2015;4(11):680–689.
   PubMedGoogle Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021–6.e8.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.
   PubMedGoogle Scholar
• Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729–736.
   PubMed Web of Science ®Google Scholar
• Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–348.
   PubMed Web of Science ®Google Scholar
• Dreno B, Basset-Seguin N, Caro I, et al. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist. 2014;19(8):790–796.
   PubMed Web of Science ®Google Scholar
• Chang AL, Lewis KD, Arron ST, et al. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma. Oncotarget. 2016;7(46):76118–76124.
   PubMedGoogle Scholar
• Basset-Séguin N, Hansson J, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial [oral presentation]. In: 25th EADV Congress. Vienna; 2016.
   Google Scholar
• Grob -J-J, Bartley K, Kuntsfeld R, et al. Assessment of quality of life (QoL) using Skindex-16 in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with vismodegib (VISMO) in the STEVIE study [abstract no. 3140]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB193.
   Web of Science ®Google Scholar
• Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404–412.
   PubMed Web of Science ®Google Scholar
• Burness CB. Sonidegib: first global approval. Drugs. 2015;75(13):1559–1566.
   PubMed Web of Science ®Google Scholar
• Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900–1909.
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Sonidegib efficacy and tolerability in advanced basal cell carcinoma: a single-center real-life experience. J Am Acad Dermatol. 2021;S0190–9622(21):02910–8.
   Google Scholar
• Zollinger M, Lozac’h F, Hurh E, et al. Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol. 2014;74(1):63–75.
   PubMed Web of Science ®Google Scholar
• Odomzo EMA summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf, checked on 2020 Mar 19
   Google Scholar
• Brancaccio G, Pea F, Moscarella E, et al. Sonidegib for the treatment of advanced basal cell carcinoma. Front Oncol. 2020;10:582866.
   PubMedGoogle Scholar
• Novartis. Odomzo® (sonidegib) capsules, for oral use: US prescribing infomation. 2015. www.odomzo.com/. Cited 2015 Jan 13 Jan 2015. 7.
   Google Scholar
• European Medicines Agency. Odomzo® 200 mg hard capsules: summary of product characteristics. 2015. http://www.ema.europa.eu/. Cited 2016 Jan 13.
   Google Scholar
• Goel V, Hurh E, Stein A, et al. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(4):745–755.
   PubMed Web of Science ®Google Scholar
• Pan S, Wu X, Jiang J, et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett. 2010;1(3):130–134.
   PubMed Web of Science ®Google Scholar
• Horsmans Y, Zhou J, Liudmila M, et al. Effects of mild to severe hepatic impairment on the pharmacokinetics of sonidegib: a multicenter, open-label, parallel-group study. Clin Pharmacokinet. 2018;57(3):345–354.
   PubMed Web of Science ®Google Scholar
• Einolf HJ, Zhou J, Won C, et al. A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients. Drug Metab Dispos. 2017;45(4):361–374.
   PubMed Web of Science ®Google Scholar
• Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–728.
   PubMed Web of Science ®Google Scholar
• Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369–1378.
   PubMed Web of Science ®Google Scholar
• Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–381.
   PubMed Web of Science ®Google Scholar
• Borradori L, Sutton B, Shayesteh P, et al. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016;175(6):1382–1386.
   PubMed Web of Science ®Google Scholar
• Falchook GS, Leidner R, Stankevich E, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016;4:70.
   PubMed Web of Science ®Google Scholar
• Niebel D, Sirokay J, Hoffmann F, et al. Clinical management of locally advanced basal-cell carcinomas and future therapeutic directions. Dermatol Ther (Heidelb). 2020;10(4):835–846.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Goodman AM, Cohen PR, et al. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016;1:16037.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Lilo MT, Ogurtsova A, et al. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer. 2017;5:23.
   PubMed Web of Science ®Google Scholar
• Cannon JGD, Russell JS, Kim J, et al. A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. JAAD Case Rep. 2018;4(3):248–250.
   PubMedGoogle Scholar
• Chen L, Aria AB, Silapunt S, et al. Emerging nonsurgical therapies for locally advanced and metastatic nonmelanoma skin cancer. Dermatol Surg. 2019;45(1):1–16.
   PubMed Web of Science ®Google Scholar
• Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019;80(2):564–566.
   PubMed Web of Science ®Google Scholar
• Moreira A, Kirchberger MC, Toussaint F, et al. Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome. Br J Dermatol. 2018;179(3):747–749.
   PubMed Web of Science ®Google Scholar
• Winkler JK, Schneiderbauer R, Bender C, et al. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2017;176(2):498–502.
   PubMed Web of Science ®Google Scholar
• Fischer S, Hasan Ali O, Jochum W, et al. Anti-PD-1 therapy leads to near-complete remission in a patient with metastatic basal cell carcinoma. Oncol Res Treat. 2018;41(6):391–394.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Bell RB, Bifulco CB, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7(1):184.
   PubMed Web of Science ®Google Scholar
• Shalhout SZ, Emerick KS, Kaufman HL, et al. Immunotherapy for non-melanoma skin cancer. Curr Oncol Rep. 2021;23(11):125.
   PubMed Web of Science ®Google Scholar
• Tillman DK Jr, Carroll MT. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol. 2008;7(1 Suppl 1):s7–14.
   PubMedGoogle Scholar
• Lucena SR, Salazar N, Gracia-Cazaña T, et al. Combined treatments with photodynamic therapy for non-melanoma skin cancer. Int J Mol Sci. 2015;16(10):25912–25933.
   PubMed Web of Science ®Google Scholar
• Osiecka B, Jurczyszyn K, Ziółkowski P. The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monit. 2012;18(2):I5–9.
   Web of Science ®Google Scholar
• Messeguer F, Serra-Guillen C, Echeverria B, et al. A pilot study of clinical efficacy of imiquimod and cryotherapy for the treatment of basal cell carcinoma with incomplete response to imiquimod. J Eur Acad Dermatol Venereol. 2012;26(7):879–881.
   PubMed Web of Science ®Google Scholar
• Gaitanis G, Bassukas ID. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter. Acta Derm Venereol. 2014;94(1):38–44.
   PubMed Web of Science ®Google Scholar
• Torres A, Niemeyer A, Berkes B, et al. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004;30(12 Pt 1):1462–1469.
   PubMed Web of Science ®Google Scholar
• Patel AD, Ravichandran S, Kheterpal M. Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma. Int J Dermatol. 2022;61(1):118–124.
   PubMed Web of Science ®Google Scholar
• Rizzo JM, Segal RJ, Zeitouni NC. Combination vismodegib and photodynamic therapy for multiple basal cell carcinomas. Photodiagnosis Photodyn Ther. 2018;21:58–62.
   PubMed Web of Science ®Google Scholar
• Thissen MR, Kuijpers DI, Krekels GA. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol. 2006;5(5):461–464.
   PubMedGoogle Scholar
• Kwon GP, Ally MS, Bailey-Healy I, et al. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC). J Am Acad Dermatol. 2016;75(1):213–215.
   PubMed Web of Science ®Google Scholar
• Zelin E, Zalaudek I, Agozzino M, et al. Neoadjuvant therapy for non-melanoma skin cancer: updated therapeutic approaches for basal, squamous, and Merkel cell carcinoma. Curr Treat Options Oncol. 2021;22(4):35.
   PubMed Web of Science ®Google Scholar
• Tang N, Ratner D. Implementation of systemic hedgehog inhibitors in daily practice as neoadjuvant therapy. J Natl Compr Canc Netw. 2017;15(4):537–543.
   PubMed Web of Science ®Google Scholar
• Curragh DS, Huilgol SC, Selva D. Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma. Eye (Lond). 2021;35(10):2740–2745.
   PubMed Web of Science ®Google Scholar
• González AR, Etchichury D, Gil ME, et al. Neoadjuvant vismodegib and mohs micrographic surgery for locally advanced periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg. 2019;35(1):56–61.
   PubMed Web of Science ®Google Scholar
• Angnardo L, Humeda Y, Alexandraki I, et al. Vismodegib as eye-sparing neoadjuvant treatment for locally advanced periocular basal cell carcinoma. J Drugs Dermatol. 2021;20(5):552–554.
   PubMed Web of Science ®Google Scholar
• Sofen H, Gross KG, Goldberg LH, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015;73(1):99–105.e1.
   PubMed Web of Science ®Google Scholar
• Ching JA, Curtis HL, Braue JA, et al. The impact of neoadjuvant hedgehog inhibitor therapy on the surgical treatment of extensive basal cell carcinoma. Ann Plast Surg. 2015;74 Suppl 4:S193–7.
   PubMed Web of Science ®Google Scholar
• Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):904–911.e1.
   PubMed Web of Science ®Google Scholar
• Kahana A, Unsworth SP, Andrews CA, et al. Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: the VISORB trial. Oncologist. 2021;26(7):e1240–e1249.
   PubMed Web of Science ®Google Scholar
• Soon SL, Ibrahim SF, Arron ST. A randomized phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned. Br J Dermatol. 2019;181(1):208–209.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Guerreschi P, Basset-Seguin N, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant vismodegib in locally advanced basal cell carcinoma. EClinicalMedicine. 2021;35:100844.
   PubMedGoogle Scholar
• Huq AJ, Walsh M, Rajagopalan B, et al. Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same. Fam Cancer. 2018;17(4):601–606.
   PubMed Web of Science ®Google Scholar
• Palacios-Álvarez I, González-Sarmiento R, Fernández-López E. Gorlin Syndrome. Actas Dermosifiliogr (Engl Ed). 2018;109(3):207–217.
   PubMed Web of Science ®Google Scholar
• Tang JY, Ally MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1720–1731.
   PubMed Web of Science ®Google Scholar
• Baker S, Joseph K, Tai P. Radiotherapy in Gorlin syndrome: can it be safe and effective in adult patients? J Cutan Med Surg. 2016;20(2):159–162.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Adam GP, Rofeberg V, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis. Ann Intern Med. 2018;169(7):456–466.
   PubMed Web of Science ®Google Scholar
• McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50(4):774–783.
   PubMed Web of Science ®Google Scholar
• Xie P, Lefrançois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(6):1089–1100.e17.
   PubMed Web of Science ®Google Scholar
• Wilson M, Johnson RP, Senft SC, et al. Advanced basal cell carcinoma: what dermatologists need to know about treatment. J Am Acad Dermatol. 2022 Jun;86(6S):S14–S24. PMID: 35577406.
   PubMedGoogle Scholar